- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Haywood Brown on the Importance of Postpartum Follow-Up
Haywood Brown, MD, immediate past president of the American College of Obstetricians and Gynecology (ACOG), discusses the importance of postpartum follow up, and the reasoning behind ACOG's recently revised committee opinion.
Transcript
ACOG recently released a revised committee opinion that proposes a new paradigm for postpartum care. What is the reason for this change?
Well this is something I’ve thought about for over a decade now— how we can improve the outcomes of women through postpartum follow up. And we’ve been stuck in the 6 weeks paradigm since the beginning of time, it seems. But really, it’s about seeing women when they need to be seen.
It’s very difficult to screen for postpartum depression if you don’t do it early. It’s very difficult to counsel women on breast feeding continuation if you don’t do it early. But once pregnancy complications occur— whether they be having a preterm baby or preeclampsia– the whole postpartum follow up really changes. The idea behind having an early visit and a later visit is so that you can discuss reproductive life planning and long-term health risks during that time period, over that 12 weeks.
Our whole objective is to do a better job with education of the patients, but also with the providers on the importance of postpartum follow up, and also guiding the principles for long-term health. That’s really the reason for the change, and that’s the reason that we proposed this for one of our task forces.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
